GRA

Grail Stock

StockStock
ISIN: US3847471014
Ticker: GRAL
US3847471014
GRAL

Price

Frequently asked questions

What is Grail's market capitalization?

The market capitalization of Grail is $422.89M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Grail?

Grail's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$99.94. EPS indicates the company's profitability on a per-share basis.

What is Grail's revenue over the trailing twelve months?

Over the trailing twelve months, Grail reported a revenue of $109.74M.

What is the EBITDA for Grail?

Grail's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$655.90M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Grail?

Grail has a free cash flow of -$676.39M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

How many employees does Grail have, and what sector and industry does it belong to?

Grail employs approximately 1,370 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Grail's shares?

The free float of Grail is 26.46M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$422.89M

EPS (TTM)

 
-$99.94

Free Float

 
26.46M

Revenue (TTM)

 
$109.74M

EBITDA (TTM)

 
-$655.90M

Free Cashflow (TTM)

 
-$676.39M

Pricing

1D span
$13.25$13.74
52W span
$12.33$23.36

Information

GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. It is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.

1,370

Biotechnology & Drugs

Health Care

Identifier

ISIN

US3847471014

Primary Ticker

GRAL

Knockouts

Join the conversation